<- Go Home
Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Market Cap
$573.5K
Volume
56.7K
Cash and Equivalents
$2.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.85
52 Week Low
$0.30
Dividend
N/A
Price / Book Value
0.23
Price / Earnings
-0.02
Price / Tangible Book Value
0.23
Enterprise Value
-$3.0M
Enterprise Value / EBITDA
N/A
Operating Income
-$11.3M
Return on Equity
931.95%
Return on Assets
-311.89
Cash and Short Term Investments
$2.6M
Debt
N/A
Equity
$1.9M
Revenue
N/A
Unlevered FCF
-$7.4M
Sector
Pharmaceuticals
Category
N/A